PubMed Health⌕ Search

PubMed · 6148718

Tardive dyskinesia: current clinical issues.

Abstract

Tardive dyskinesia (TD) consists of persistent involuntary movements that are due to antipsychotic drug treatment. Prevention depends on accurate psychiatric diagnosis and use of antipsychotics only for specific indications. Little is known about what antipsychotic drug regimens affect the risk of TD. Clinical subtypes of TD may exist. Tardive dystonia differs from oral choreic TD in its clinical phenomenology, epidemiology, and clinical pharmacology. Another possible subtype, persistent motor restlessness, seems also distinguishable in its phenomenology and epidemiology. Both of these forms of TD can be disabling, whereas typical oral TD often is not. Although TD may spontaneously remit more often than was once believed, it nevertheless is often persistent. No current therapy is universally effective.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R E Burke. 1984. Tardive dyskinesia: current clinical issues.. https://doi.org/10.1212/wnl.34.10.1348

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Differential pharmacology of atypical antipsychotics: clinical implications.

PURPOSE: Pharmacology of atypical antipsychotics and the clinical implications are reviewed. SUMMARY: Psychiatric disorders, such as schizophrenia and bipolar disorder, are often associated with poor outcomes. Atypical antipsychotics have become the standard of care for these disorders, and multiple agents have demonstrated efficacy for both acute and maintenance therapy. As a result of their differential pharmacologic properties, atypical antipsychotics have diverse clinical profiles, resulting in different liabilities for specific adverse events. These effects can, in turn, have an adverse impact on patient functionality, adherence to therapy, and overall health. CONCLUSION: Atypical antipsychotics have distinct pharmacological profiles which result in clinically meaningful differences in adverse effects. Clinicians should have a wide choice of agents available with which to optimize outcomes in the majority of patients with psychiatric disorders.

Antipsychotic Agents↗